RG 6100

Drug Profile

RG 6100

Alternative Names: anti-tau monoclonal antibody - AC Immune/Genentech; RG6100; RO 7105705

Latest Information Update: 22 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AC Immune
  • Developer Genentech
  • Class Antidementias; Monoclonal antibodies
  • Mechanism of Action Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease

Most Recent Events

  • 22 Sep 2017 Phase-II clinical trials in Alzheimer's disease in USA (IV) (NCT03289143)
  • 26 Jun 2017 Genentech completes a phase I trial in Alzheimer's disease in USA (SC) (IV) (NCT02820896)
  • 30 Jun 2016 Phase-I clinical trials in Alzheimer's disease in USA (IV, Infusion) (NCT02820896)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top